SMURF2 Antibody - #DF7683

(2)   (6)  
Product: SMURF2 Antibody
Catalog: DF7683
Description: Rabbit polyclonal antibody to SMURF2
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Chicken, Xenopus
Mol.Wt.: 86 kDa; 86kD(Calculated).
Uniprot: Q9HAU4
RRID: AB_2841154

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IF/ICC 1:100-500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Zebrafish(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Chicken(100%), Xenopus(100%)
Clonality:
Polyclonal
Specificity:
SMURF2 Antibody detects endogenous levels of total SMURF2.
RRID:
AB_2841154
Cite Format: Affinity Biosciences Cat# DF7683, RRID:AB_2841154.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

E3 ubiquitin-protein ligase SMURF2; EC 6.3.2.; hSMURF2; MGC138150; Smad specific E3 ubiquitin ligase 2; SMAD specific E3 ubiquitin protein ligase 2; SMAD ubiquitination regulatory factor 2; SMAD-specific E3 ubiquitin-protein ligase 2; SMUF2_HUMAN; Smurf2; Ubiquitin protein ligase SMURF2;

Immunogens

Immunogen:
Uniprot:

Q9HAU4(SMUF2_HUMAN) >>Visit HPA database.

Gene(ID):
SMURF2(64750)
Expression:
Q9HAU4 SMUF2_HUMAN:

Widely expressed.

Sequence:
MSNPGGRRNGPVKLRLTVLCAKNLVKKDFFRLPDPFAKVVVDGSGQCHSTDTVKNTLDPKWNQHYDLYIGKSDSVTISVWNHKKIHKKQGAGFLGCVRLLSNAINRLKDTGYQRLDLCKLGPNDNDTVRGQIVVSLQSRDRIGTGGQVVDCSRLFDNDLPDGWEERRTASGRIQYLNHITRTTQWERPTRPASEYSSPGRPLSCFVDENTPISGTNGATCGQSSDPRLAERRVRSQRHRNYMSRTHLHTPPDLPEGYEQRTTQQGQVYFLHTQTGVSTWHDPRVPRDLSNINCEELGPLPPGWEIRNTATGRVYFVDHNNRTTQFTDPRLSANLHLVLNRQNQLKDQQQQQVVSLCPDDTECLTVPRYKRDLVQKLKILRQELSQQQPQAGHCRIEVSREEIFEESYRQVMKMRPKDLWKRLMIKFRGEEGLDYGGVAREWLYLLSHEMLNPYYGLFQYSRDDIYTLQINPDSAVNPEHLSYFHFVGRIMGMAVFHGHYIDGGFTLPFYKQLLGKSITLDDMELVDPDLHNSLVWILENDITGVLDHTFCVEHNAYGEIIQHELKPNGKSIPVNEENKKEYVRLYVNWRFLRGIEAQFLALQKGFNEVIPQHLLKTFDEKELELIICGLGKIDVNDWKVNTRLKHCTPDSNIVKWFWKAVEFFDEERRARLLQFVTGSSRVPLQGFKALQGAAGPRLFTIHQIDACTNNLPKAHTCFNRIDIPPYESYEKLYEKLLTAIEETCGFAVE

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Xenopus
100
Zebrafish
100
Chicken
100
Rabbit
100
Dog
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9HAU4 As Substrate

Site PTM Type Enzyme
K26 Sumoylation
K38 Ubiquitination
S44 Phosphorylation
T144 Phosphorylation
T168 Phosphorylation
S170 Phosphorylation
S203 Phosphorylation
R232 Methylation
R234 Methylation
R237 Methylation
R239 Methylation
T249 Phosphorylation
K369 Sumoylation
K375 Ubiquitination
K377 Ubiquitination
S406 Phosphorylation
Y407 Phosphorylation
K412 Ubiquitination
Y434 Phosphorylation
Y499 Phosphorylation
K578 Ubiquitination
K579 Ubiquitination
K638 Ubiquitination
K730 Ubiquitination
K734 Ubiquitination

Research Backgrounds

Function:

E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Interacts with SMAD1 and SMAD7 in order to trigger their ubiquitination and proteasome-dependent degradation. In addition, interaction with SMAD7 activates autocatalytic degradation, which is prevented by interaction with SCYE1. Forms a stable complex with the TGF-beta receptor-mediated phosphorylated SMAD2 and SMAD3. In this way, SMAD2 may recruit substrates, such as SNON, for ubiquitin-mediated degradation. Enhances the inhibitory activity of SMAD7 and reduces the transcriptional activity of SMAD2. Coexpression of SMURF2 with SMAD1 results in considerable decrease in steady-state level of SMAD1 protein and a smaller decrease of SMAD2 level. Negatively regulates TGFB1-induced epithelial-mesenchymal transition and myofibroblast differentiation.

PTMs:

Auto-ubiquitinated and ubiquitinated in the presence of RNF11 and UBE2D1. Ubiquitinated by the SCF(FBXL15) complex and TTC3, leading to its degradation by the proteasome.

Subcellular Location:

Nucleus. Cytoplasm. Cell membrane. Membrane raft.
Note: Cytoplasmic in the presence of SMAD7. Colocalizes with CAV1, SMAD7 and TGF-beta receptor in membrane rafts.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Widely expressed.

Subunit Structure:

Interacts (via WW domains) with SMAD1. Interacts (via WW domains) with SMAD2 (via PY-motif). Interacts (via WW domains) with SMAD3 (via PY-motif). Interacts with SMAD6. Interacts with SMAD7 (via PY-motif) and TGFBR1; SMAD7 recruits SMURF2 to the TGF-beta receptor and regulates its degradation. Does not interact with SMAD4; SMAD4 lacks a PY-motif. Interacts with AIMP1. Interacts with STAMBP and RNF11. Interacts with NDFIP1 and NDFIP2 (Probable); this interaction activates the E3 ubiquitin-protein ligase. Interacts with TTC3.

Family&Domains:

The second and third WW domains are responsible for interaction with the PY-motif of R-SMAD (SMAD1, SMAD2 and SMAD3).

The C2 domain is involved in autoinhibition of the catalytic activity by interacting with the HECT domain.

Research Fields

· Cellular Processes > Transport and catabolism > Endocytosis.   (View pathway)

· Environmental Information Processing > Signal transduction > Hedgehog signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway.   (View pathway)

· Genetic Information Processing > Folding, sorting and degradation > Ubiquitin mediated proteolysis.   (View pathway)

References

1). CBX3 Regulated By YBX1 Promotes Smoking-induced Pancreatic Cancer Progression via Inhibiting SMURF2 Expression. International Journal of Biological Sciences, 2022 (PubMed: 35637952) [IF=9.2]

Application: WB    Species: Human    Sample: pancreatic cancer cells

Fig 6 The YBX1/CBX3 axis promotes tumor growth via suppressing SMURF2 in pancreatic cancer. (A-D) PANC-1 and SW1990 cells were transfected with indicated shRNAs for 72 hours. After puromycin selection, cells were harvested for the RT-qPCR (A), MTS (B), and colony formation (C and D). (E-G) PANC-1 cells were transfected with indicated shRNAs for 72 hours. After puromycin selection, cells were subcutaneously injected into the nude mice. The image of tumor was shown in panel E. The tumor mass and tumor growth curve were demonstrated in panel F and G, respectively. Data are presented as mean ± SD (n = 5). (H) PANC-1 and BxPC-3 cells were transfected with indicated shRNAs for 72 hours. After puromycin selection, cells were harvested for the Western blot analysis. (I) PANC-1 and BxPC-3 cells were transfected with indicated shRNAs for 48 hours, and then were transfected with indicated constructs for another 24 hours. Cells were harvested for Western blot. (J) A hypothetic model depicted that CSE exposure-induced YBX1 overexpression contributed to the upregulation of CBX3, which inhibited SMURF2 expression to promote the progression of pancreatic cancer. Data in (A), (B) and (D) are presented as mean ± SD (n = 3). Not significant Ns; P < 0.001 ***.
2). TFPI2 suppresses the interaction of TGF-β2 pathway regulators to promote endothelial-mesenchymal transition in diabetic nephropathy. Journal of Biological Chemistry, 2022 (PubMed: 35157852) [IF=4.8]

Application: WB    Species: Human    Sample: hRGECs

Figure 7 TGF-β2 induces expression of TFPI2 in vitro. Human renal glomerular endothelial cells (hRGECs) were incubated with human recombinant protein TGF-β2 to induce EndMT in vitro. A, the expression of TFPI2 and SMURF2 in hRGECs following treatment of 0, 1, 2.5, 5, or 10 ng/ml TGF-β2 for 48 h. B, the expression of TFPI2 and SMURF2 in hRGECs following treatment of 5 ng/ml TGF-β2 for 0, 12, 24, or 48 h. To explore the molecular mechanism of TGF-β2-induced TFPI2 expression, we next verified whether TFPI2 is a direct target gene of TGF-β/Smad signal. According to JASPAR prediction, TFPI2 is a potential target gene of SMAD2/3/4. C, the promoter activity of TFPI2 gene under TGF-β2 stimulation was detected by Dual-Luciferase Reporter Assay. D, SMAD4 was knocked down in hRGECs in the presence of TGF-β2, which was confirmed by Western blot. E, the expression of TFPI2 was detected in SMAD4-silencing cells. Data are shown as the mean ± SD (n = 3). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. hRGEC, human renal glomerular endothelial cell; SMURF2, SMAD ubiquitination regulatory factor-2; TFP12, tissue factor pathway inhibitor 2; TGF-β, transforming growth factor beta.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.